TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6185060

Group type: EXPERIMENTAL
Intervention: Loperamide at a dose of 0.2 mg/kg/day
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 30592390

Group type: EXPERIMENTAL
Intervention: Repeated umbilical cord-derived mesenchymal stromal cells (UC-MSCs) at baseline and 6 months (20 × 10^6 × 2)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Single-dose umbilical cord-derived mesenchymal stromal cells (UC-MSCs) at baseline (20 × 10^6)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Hyaluronic acid at baseline and 6 months
Number of subjects: 26
Study: 28764646

Group type: EXPERIMENTAL
Intervention: Ganaxolone
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 27378488

Group type: EXPERIMENTAL
Intervention: High extratextual engagement strategies including verbal responsiveness
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moderate extratextual engagement strategies including verbal responsiveness
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low extratextual engagement strategies including verbal responsiveness
Number of subjects: 0
Study: 25256258

Group type: EXPERIMENTAL
Intervention: Abediterol 5 μg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Abediterol 10 μg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Abediterol 25 μg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Salmeterol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21450214

Group type: EXPERIMENTAL
Intervention: Epoetin alfa (20,000 international units subcutaneously every 2 weeks, extended to every 4 weeks based on Hb levels)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Number of subjects: 157

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 157
Study: 18375537

Group type: EXPERIMENTAL
Intervention: 500 microg icatibant (group B)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 2000 microg icatibant (group C)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo (group A)
Number of subjects: 41
Study: 17241864

Group type: EXPERIMENTAL
Intervention: Reducing peginterferon alfa-2a dose to < or =60%
Number of subjects: 936

Group type: COMPARATOR
Intervention: Full-dose peginterferon alfa-2a (> or =98%) with ribavirin dose reduced to < or =60%
Number of subjects: 936

Group type: COMPARATOR
Intervention: Full-dose peginterferon alfa-2a with prematurely discontinued ribavirin
Number of subjects: 936
Study: 15096814

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 12061970

Group type: EXPERIMENTAL
Intervention: Amodiaquine with pyrimethamine-sulfadoxine (AQPS)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Chloroquine (CQ)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Chloroquine with pyrimethamine-sulfadoxine (CQPS)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Amodiaquine (AQ)
Number of subjects: 303
Study: 9794671

Group type: EXPERIMENTAL
Intervention: 200 microg of misoprostol
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 400 microg of misoprostol
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 600 microg of misoprostol
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 800 microg of misoprostol
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Comparison of 400 microg and 600 microg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Comparison of 600 microg and 800 microg
Number of subjects: 120
Study: 7697848

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg rPF4
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg rPF4
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 2.5 mg/kg rPF4
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 5.0 mg/kg rPF4
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: rPF4 administration
Number of subjects: 18
Study: 2665662

Group type: EXPERIMENTAL
Intervention: Casein based formula
Number of subjects: 173

Group type: COMPARATOR
Intervention: Whey based formula
Number of subjects: 173
Study: 856012

Group type: EXPERIMENTAL
Intervention: Netilmicin
Number of subjects: 13

Group type: COMPARATOR
Intervention: Gentamicin
Number of subjects: 13
Study: 31910895

Group type: EXPERIMENTAL
Intervention: Methylphenidate (10 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Galantamine (16 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 30279028

Group type: EXPERIMENTAL
Intervention: Education program and telephone call follow-up
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 116
Study: 28301264

Group type: EXPERIMENTAL
Intervention: Radiation therapy with a median prescription dose of 70 Gy
Number of subjects: 125

Group type: COMPARATOR
Intervention: Pre-existing cardiac disease
Number of subjects: 125

Group type: COMPARATOR
Intervention: Mean heart dose
Number of subjects: 125

Group type: COMPARATOR
Intervention: Disease progression
Number of subjects: 125

Group type: COMPARATOR
Intervention: Grade ≥ 3 cardiac events
Number of subjects: 125
Study: 25935340

Group type: EXPERIMENTAL
Intervention: Preoperative hyperosmotic treatment with sodium chloride 5% ophthalmic ointment (Muro‐128)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Control eyes (no hyperosmotic treatment)
Number of subjects: 248
Study: 23806384

Group type: EXPERIMENTAL
Intervention: Dietary nitrate (250 ml beetroot juice)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Potassium nitrate capsules (KNO3, 8 mmol)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 24
Study: 21457238

Group type: EXPERIMENTAL
Intervention: telcagepant + ibuprofen 280 mg + ibuprofen 400 mg
Number of subjects: 683

Group type: EXPERIMENTAL
Intervention: telcagepant + acetaminophen 280 mg + acetaminophen 1000 mg
Number of subjects: 683

Group type: EXPERIMENTAL
Intervention: telcagepant 280 mg
Number of subjects: 683

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 683
Study: 19837304

Group type: COMPARATOR
Intervention: Platelet-rich plasma (PRP) alone
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) with resorbable collagen membrane (Bio-Gide)
Number of subjects: 18
Study: 17702703

Group type: EXPERIMENTAL
Intervention: Conventional therapy plus an additional session of standing practice
Number of subjects: 17

Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 17
Study: 15383482

Group type: EXPERIMENTAL
Intervention: IV tissue plasminogen activator (tPA) if treatment is initiated within 3 h of symptom onset
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thrombolytic therapy for patients with extensive and clearly identifiable hypodensity on CT
Number of subjects: 0

Group type: COMPARATOR
Intervention: IV tPA for unselected patients with AIS of > 3 h but < 6 h
Number of subjects: 0

Group type: COMPARATOR
Intervention: Streptokinase
Number of subjects: 0

Group type: COMPARATOR
Intervention: Full-dose anticoagulation with IV or subcutaneous heparins or heparinoids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early aspirin therapy, 160 to 325 mg qd
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prophylactic low-dose subcutaneous heparin or low molecular weight heparins or heparinoids for AIS patients with restricted mobility
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression devices or elastic stockings for patients with contraindications to anticoagulants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression for patients with acute intracerebral hematoma
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antiplatelet agent treatment (including aspirin, combination of aspirin and extended-release dipyridamole, or clopidogrel) for noncardioembolic stroke or TIA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of aspirin and extended-release dipyridamole over aspirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clopidogrel over aspirin for noncardioembolic stroke or TIA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clopidogrel for patients allergic to aspirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-term oral anticoagulation for patients with atrial fibrillation and a recent stroke or TIA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin or low molecular weight heparin for patients with venous sinus thrombosis during the acute phase
Number of subjects: 0
Study: 11422739

Group type: EXPERIMENTAL
Intervention: Angiotensin II infusion
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Angiotensin II infusion with AT1R blockade
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 9
Study: 9865645

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin hydrochloride, 400 mg every 12 hours, and metronidazole hydrochloride, 500 mg every 6 hours
Number of subjects: 84

Group type: COMPARATOR
Intervention: Gentamicin sulfate, 2.5 mg/kg every 12 hours, and metronidazole hydrochloride, 500 mg every 6 hours
Number of subjects: 84
Study: 7878282

Group type: EXPERIMENTAL
Intervention: Isosorbide-5-mononitrate (IS-5-MN) 40 mg/12 hours
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Isosorbide-5-mononitrate (IS-5-MN) 40 mg/8 hours
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 2368896

Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 0
Study: 383704

Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 28

Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 31613346

Group type: EXPERIMENTAL
Intervention: Energy-reduced Mediterranean diet, physical activity promotion, and behavioral support (n=3406)
Number of subjects: 6874

Group type: COMPARATOR
Intervention: Energy-unrestricted Mediterranean diet (control group, n=3468)
Number of subjects: 6874

Group type: COMPARATOR
Intervention: Comparison of both groups
Number of subjects: 6874
Study: 28844985

Group type: EXPERIMENTAL
Intervention: FAmily CEntered disease-specific advance care planning (ACP) for teens with cancer (FACE-TC)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 260
Study: 25888180

Group type: EXPERIMENTAL
Intervention: Antibiotic checklist implementation
Number of subjects: 810
Study: 22859496

Group type: COMPARATOR
Intervention: 180 μg PegIFN for 48 weeks
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: 180 μg PegIFN for 48 weeks followed by 135 μg weekly for an additional 48 weeks
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: 180 μg PegIFN plus lamivudine for 48 weeks then 135 μg PegIFN for 48 weeks
Number of subjects: 128
Study: 21474574

Group type: EXPERIMENTAL
Intervention: SHSe reduction coaching
Number of subjects: 201

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 201
Study: 20234035

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (2.25 g) plus policosanol (10 mg) for 21 days
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (oleic sunflower oil)
Number of subjects: 18
Study: 17823447

Group type: EXPERIMENTAL
Intervention: Low-fat fermented milk enriched with 0.8 g plant sterol (PS) ester per portion, consumed daily for 6 weeks
Number of subjects: 194

Group type: COMPARATOR
Intervention: Control low-fat fermented milk, consumed daily for 6 weeks
Number of subjects: 194
Study: 15061267

Group type: EXPERIMENTAL
Intervention: SPECT images using fan-beam collimators with scatter and attenuation corrections
Number of subjects: 11

Group type: COMPARATOR
Intervention: SPECT images using parallel-hole collimators without any correction
Number of subjects: 11
Study: 11231850

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Surgeon
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: First assistant
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: More experienced surgeon
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Less experienced surgeon
Number of subjects: 20
Study: 11522565

Group type: EXPERIMENTAL
Intervention: High-fiber, high-fruit-and-vegetable, low-fat diet (4.30 g/MJ fiber, 0.84 servings/MJ fruit and vegetables, 20% of energy from fat)
Number of subjects: 2079

Group type: COMPARATOR
Intervention: Control group (standard diet)
Number of subjects: 2079
Study: 9051389

Group type: EXPERIMENTAL
Intervention: 800 mg ALA daily for 4 months
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 8330461

Group type: EXPERIMENTAL
Intervention: Quinine (oral doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quinidine (oral doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amantadine (baseline)
Number of subjects: 0
Study: 2451815

Group type: EXPERIMENTAL
Intervention: Flupirtine (80 mg i.v.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pentazocine (30 mg i.v.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2551070

Group type: EXPERIMENTAL
Intervention: 75 XaI U/kg b.w. twice daily Logiparin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 150 XaI U/kg b.w. once daily Logiparin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Logiparin treatment
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Logiparin
Number of subjects: 20
Study: 31933342

Group type: EXPERIMENTAL
Intervention: Single-strap bag
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Double-strap bag
Number of subjects: 16

Group type: COMPARATOR
Intervention: Unloaded condition
Number of subjects: 16
Study: 28702852

Group type: EXPERIMENTAL
Intervention: Integrated TD/IMB intervention (experimental group)
Number of subjects: 84

Group type: COMPARATOR
Intervention: IMB-guided sexual risk reduction (control group)
Number of subjects: 84
Study: 26498746

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 128
Study: 23677816

Group type: EXPERIMENTAL
Intervention: Pharmaceutical care intervention including medication review, education on osteoporosis, risk factors, lifestyle modifications, goals of therapy, side effects, and importance of medication adherence at months 0, 3, 6, and 12
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Pharmaceutical care intervention
Number of subjects: 198

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 198
Study: 21308343

Group type: EXPERIMENTAL
Intervention: Educational nursing intervention during hospitalization followed by telephone monitoring after discharge (Intervention Group - IG)
Number of subjects: 111

Group type: COMPARATOR
Intervention: In-hospital intervention only (Control Group - CG)
Number of subjects: 111
Study: 19824379

Group type: EXPERIMENTAL
Intervention: Standard therapy plus ovestin (daily intravaginal administration for 2 weeks, then twice a week)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 102
Study: 17525699

Group type: EXPERIMENTAL
Intervention: Neck muscle training
Number of subjects: 118
Study: 15208504

Group type: EXPERIMENTAL
Intervention: 99mTc‐L,L‐EC scan
Number of subjects: 82

Group type: COMPARATOR
Intervention: 99mTc‐DMSA scan
Number of subjects: 82
Study: 11588692

Group type: EXPERIMENTAL
Intervention: Ramoplanin 100 mg
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Ramoplanin 400 mg
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 9613276

Group type: EXPERIMENTAL
Intervention: Epidural blockade with 0.9% saline (16 ml) prior to incision and 0.5% bupivacaine (15 ml) + fentanyl 50 micrograms (1 ml) prior to closure.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Epidural blockade with 0.5% bupivacaine (15 ml) + fentanyl 50 micrograms (1 ml) prior to incision and 0.9% saline prior to closure.
Number of subjects: 50
Study: 7570844

Group type: EXPERIMENTAL
Intervention: Ivermectin treatment
Number of subjects: 0
Study: 2782692

Group type: COMPARATOR
Intervention: Seldinger technique (Seldicath Plastimed, FG 3, 80 mm long; group S; n = 30)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: New arterial catheter (Arrow, Critikon, gauge 20, 44 mm long; group A; n = 30)
Number of subjects: 60
Study: 766679

Group type: EXPERIMENTAL
Intervention: Allergy prick tests
Number of subjects: 3101
Study: 30339878

Group type: EXPERIMENTAL
Intervention: Single‐piece acrylic intraocular lens (IOL; SA60AT; Alcon Laboratories)
Number of subjects: 930

Group type: EXPERIMENTAL
Intervention: Three‐piece acrylic IOL (MA60AS; Alcon Laboratories)
Number of subjects: 930

Group type: EXPERIMENTAL
Intervention: Capsular tension ring (randomized within pseudoexfoliation group)
Number of subjects: 930

Group type: COMPARATOR
Intervention: Control group (cataract without pseudoexfoliation)
Number of subjects: 930
Study: 27349220

Group type: EXPERIMENTAL
Intervention: Low-volume oral sulfate solution (OSS)
Number of subjects: 210

Group type: COMPARATOR
Intervention: 4-L polyethylene glycol (PEG)
Number of subjects: 210
Study: 26297239

Group type: EXPERIMENTAL
Intervention: Discharge medication counselling and medication review by a clinical pharmacist
Number of subjects: 183

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 183
Study: 23947774

Group type: EXPERIMENTAL
Intervention: Structured communication approach (DIALOG) with principles of solution-focused therapy, 6 meetings over 6 months
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 96
Study: 21324674

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZA) 4 mg intravenous every 3 months for 2 years (arm A)
Number of subjects: 439

Group type: COMPARATOR
Intervention: Control group (arm B) receiving ZA 1 year after randomization
Number of subjects: 439
Study: 19770811

Group type: EXPERIMENTAL
Intervention: Johnson & Johnson ACUVUE OASYS with HYDRACLEAR PLUS (OAS)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: CIBA Vision Night & Day (ND)
Number of subjects: 40

Group type: COMPARATOR
Intervention: CIBA Vision O2OPTIX (O2)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Johnson & Johnson ACUVUE ADVANCE with HYDRACLEAR (ADV)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Bausch & Lomb PureVision (PV)
Number of subjects: 40
Study: 17296236

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg ketamine administered into the tonsillar region
Number of subjects: 60

Group type: COMPARATOR
Intervention: 2 ml 0.9% saline administered into the tonsillar region
Number of subjects: 60
Study: 15538230

Group type: EXPERIMENTAL
Intervention: Watchful waiting policy
Number of subjects: 191
Study: 11495480

Group type: EXPERIMENTAL
Intervention: Methacholine challenge
Number of subjects: 105
Study: 9721054

Group type: EXPERIMENTAL
Intervention: Electrical stimulation on both quadriceps muscles for 8 weeks (group EXP)
Number of subjects: 14

Group type: COMPARATOR
Intervention: No electrical stimulation (group CONT)
Number of subjects: 14
Study: 7991755

Group type: EXPERIMENTAL
Intervention: Multidisciplinary community-based team (Early Intervention Service)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional hospital-based psychiatric services
Number of subjects: 100
Study: 3141220

Group type: EXPERIMENTAL
Intervention: hFSH/hMG on days 3 and 4 of the cycle followed by two ampules of hMG daily
Number of subjects: 11

Group type: COMPARATOR
Intervention: Constant daily dose of 2 ampules of hMG
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: hFSH/hMG
Number of subjects: 11

Group type: COMPARATOR
Intervention: hMG
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: hFSH/hMG and hMG
Number of subjects: 11
Study: 31141079

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound guided coil plus cyanoacrylate
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional cyanoacrylate technique
Number of subjects: 32
Study: 28782603

Group type: EXPERIMENTAL
Intervention: Epidural Analgesia (EA)
Number of subjects: 87
Study: 26439234

Group type: EXPERIMENTAL
Intervention: Exercise with Animal-Assisted Therapy (E+ATT; n = 8)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Exercise only (E; n = 7)
Number of subjects: 15
Study: 25468616

Group type: EXPERIMENTAL
Intervention: Late umbilical cord clamping (3 minutes after delivery)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Early umbilical cord clamping (10 seconds after delivery)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Late umbilical cord clamping
Number of subjects: 56

Group type: COMPARATOR
Intervention: Early umbilical cord clamping
Number of subjects: 56
Study: 21723684

Group type: EXPERIMENTAL
Intervention: Low volume contrast media (0.5 ml/kg) and low kV (100) in group B
Number of subjects: 41

Group type: COMPARATOR
Intervention: Standard volume contrast media (1 ml/kg) and standard kV (120) in group A
Number of subjects: 41
Study: 19114966

Group type: EXPERIMENTAL
Intervention: Vitamin E (400 IU) daily for five days during two menstrual cycles
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo (identical in appearance to vitamin E) daily for five days during two menstrual cycles
Number of subjects: 72
Study: 17689112

Group type: EXPERIMENTAL
Intervention: PTA (Percutaneous Transluminal Angioplasty)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: PTA+EVBT (Percutaneous Transluminal Angioplasty + Endovascular Brachytherapy)
Number of subjects: 20
Study: 15322504

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (dalteparin)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 37
Study: 11522160

Group type: EXPERIMENTAL
Intervention: Community-based lay health worker outreach
Number of subjects: 1599

Group type: EXPERIMENTAL
Intervention: Clinic-based provider training and reminder system
Number of subjects: 1599

Group type: EXPERIMENTAL
Intervention: Patient navigator for follow-up of abnormal screening results
Number of subjects: 1599

Group type: COMPARATOR
Intervention: Non-English-speaking Latinas
Number of subjects: 1599

Group type: COMPARATOR
Intervention: Non-English-speaking Chinese women
Number of subjects: 1599

Group type: COMPARATOR
Intervention: Blacks
Number of subjects: 1599
Study: 9509802

Group type: EXPERIMENTAL
Intervention: Tirilazad mesylate (6 mg/kg per day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study: 8047199

Group type: EXPERIMENTAL
Intervention: Fingertip pulsed Doppler (FPD) 5 MHz probe
Number of subjects: 12

Group type: COMPARATOR
Intervention: Blind standard punctures
Number of subjects: 12